Navigation Links
GlySure Earns ISO 13485 Certification
Date:3/5/2013

OXFORD, England, March 5, 2013 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced that it has achieved ISO 13485 certification, the global standard for the requirements of a quality management system for the design, manufacture and distribution of medical devices. By establishing a quality management system that meets international regulatory and customer requirements, GlySure has set the foundation for its European clinical trials.

"This is an exciting time for our company as we conclude our prototype trials and turn our sights toward securing a CE mark," said GlySure CEO Chris Jones . "ISO 13485 certification is a key step in this transition as it validates our quality management system and ability to consistently deliver safe and effective technologies to the global marketplace."

GlySure's continuous blood glucose monitoring (CBGM) technology meets the clinically documented need for Tight Glycemic Control (TGC) in the Intensive Care Unit (ICU), which has been shown to improve outcomes, reduce mortality and cut the cost of care.

ISO certification is the latest in a series of recent key achievements for GlySure as it prepares for regulatory trials. Over the past year the company has expanded its manufacturing, quality and development teams, opened a new manufacturing facility in Oxfordshire, England and is nearing completion of pre-clinical trials in over 120 ICU patients. GlySure anticipates that it will begin CE mark trials of its CGM system in the second quarter of 2013.

For more information on GlySure, TGC and CBGM technology, visit http://www.glysure.com.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company has demonstrated through ICU testing highly accurate sensors, which can provide continuous glucose readings throughout the length of a patient's stay in the ICU. GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 23 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Company Contact: Chris Jones , CEO, GlySure. Tel: +44(0)1235-462-870. cjones@glysure.com
Media Contact: Bruce Dodworth , Sea Glass PR. Tel: +44(0)1780-758555. bruce@seaglasspr.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arkansas Prostate Cancer Center Earns High Honor of ACR-ASTRO Accreditation
2. ZirMeds SaaS Solution Earns EHNAC HNAP Certification
3. Cardiac Science Earns Top Marks for Cardiac Stress Test, Telemetry Monitor Systems
4. Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
5. MedicareBlue Rx Drug Plan Earns Federal Governments Top Rating
6. Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline
7. Plainfield Precision Achieves ISO 13485:2003 Quality Management Certification for Medical Device Manufacturing
8. Solos Endoscopy and TUV SUD America Schedule Stage 1 ISO 13485 Audit for February 26, 2013
9. MDI Announces ISO 13485 Certification
10. GPMG Product Helps Medical Device Specification Developers be FDA and ISO 13485 Compliant
11. PDR and the iHealth Alliance Announce New Drug Safety Certification for EHRs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... BOCA RATON, Fla. , Jan. 19, 2017 ... ), a medical device company specializing in the ... conditions, such as keloids, with superficial radiation therapy, ... quarter and full year 2016 financial results on Thursday, ... The Company will hold a conference call ...
(Date:1/19/2017)... January 19, 2017 New ... to Address Motor Symptoms and Motor Complications in ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) C ... European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
(Date:1/19/2017)... -- The Global Therapy Partnering Terms and Agreements since ... and agreements entered into by the world,s leading healthcare ... deals by value - Deals listed by company A-Z, ... report provides understanding and access to the partnering deals ... companies. The report provides an analysis of partnering ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 20, 2017 , ... D R Burton Healthcare Products LLC, ... featured in a study indicating superior performance against competitive products in secretion clearance. ... Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the winter ...
(Date:1/20/2017)... ... 20, 2017 , ... “The Land of More and More”: a brilliant ... hunger, and shares the simple and achievable answer. “The Land of More and More” ... Fairview Missionary Church in Angola, Indiana where he works with the children’s ministry department. ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the fear ... political games that circumvent health needs of over 30 million. Many interviews with Dr. ... and needs government public servants were suppose to prioritize. Interviews provided below. ...
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots , ... from around the world, announces the launch of its newly redesigned website. The ... to research breakthroughs and trending news, vital information on upcoming virtual events and ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will ... version of the clinic’s leading recovery program. , “We know it’s easy ...
Breaking Medicine News(10 mins):